Aclaris therapeutics reports second quarter 2025 financial results and provides corporate update

- positive clinical results from phase 2a trial of itk/jak3 inhibitor ati-2138 confirm tolerability profile, show strong efficacy signal, and validate itk as therapeutic target - - advanced anti-tslp monoclonal antibody bosakitug (ati-045) into phase 2 trial in atopic dermatitis (ad); patient dosing underway - - initiated dosing in phase 1a/1b clinical program for anti-tslp/il-4r bispecific antibody ati-052 - - strong cash runway expected to fund operations into the second half of 2028 - wayne, pa., aug. 07, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2025 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking